✦ LIBER ✦

Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome

✍ Scribed by Harold E. Bays; Arvind Shah; Jianxin Lin; Christine McCrary Sisk; John F. Paolini; Darbie Maccubbin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lipid-modifying efficacy and tolerabilit

✍ D. Maccubbin; H. E. Bays; A. G. Olsson; V. Elinoff; A. Elis; Y. Mitchel; W. Sira 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB

Safety of extended-release niacin/laropi

✍ James McKenney; Harold Bays; Michael Koren; Christie M. Ballantyne; John F. Paol 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 404 KB

SAFETY PROFILE OF EXTENDED-RELEASE NIACI

✍ McKenney, J.; Bays, H.; Koren, M.; Ballantyne, C.; Maccubbin, D.; Mitchel, Y.; B 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 218 KB

Effects of Extended-Release Niacin with

📂 Article 📅 2014 🏛 Massachusetts Medical Society 🌐 English ⚖ 585 KB

42 Extended-Release Niacin/Laropiprant L

✍ Prerna Ganjoo; Diane Tipping; Andrew M. Tershakovec; Andrew G. Bostom 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Lipid-modifying efficacy of extended rel

✍ Debra Kush; Hyo-Soo Kim; Da Yi Hu; Ji Liu; Waheeda Sirah; Aditi Sapre; Christine 📂 Article 📅 2009 🏛 Elsevier 🌐 English ⚖ 254 KB